We hope to see you again soon!

You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.

UK-NOTPR-1010 | April 2022

Continue

Cancel

Products

Names and Compounds of our Products 

Lundbeck has a broad range of products within brain diseases. With registered products in more than 100 countries, we leverage our global presence to bring innovative therapies to people living with brain diseases around the world. 

Report An Adverse Event:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

 

Adverse events should also be reported to Lundbeck Limited, Medical Information on 01908 638972 or at SafetyLuUnitedKingdom@lundbeck.com.

Report an Adverse Drug Reaction

Reporting of potential adverse drug reactions is important in order for us to continuously evaluate the benefits and risks of our products and take proactive action as warranted.

Lundbeck Ltd UK Distributed or Promoted Products, February 2022

All our products are prescription-only medicines (POM). If more information is required, please refer to the local Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) using the links below.

 

Abilify® (aripiprazole)*

Presentations:
Abilify® contains the active substance aripiprazole.
It is available in different forms (e.g. tablets, intramuscular injection and oral solution).                                          

*Abilify® is marketed jointly with Otsuka who are the Marketing Authorisation (MA) holder

SPC & PIL Links:

Click here for the Abilify 5mg tablets SPC

Click here for the Abilify 10mg tablets SPC

Click here for the Abilify 15mg tablets SPC

Click here for the Abilify tablets 30mg SPC

Click here for the Abilify tablets PIL

Click here for the Abilify oral solution SPC

Click here for the Abilify oral solution PIL

Click here for the Abilify solution for injection SPC

Click here for the Abilify solution for injection PIL

Abilify Maintena® (aripiprazole)*   

 

Presentations: 
Abilify Maintena® contains the active substance aripiprazole.
It is available as a powder and solvent to be made into a suspension for injection.

*Abilify Maintena® is marketed jointly with Otsuka who are the MA holder.

 

SPC & PIL Links: 

Click here for the Abilify Maintena SPC

Click here for the Abilify Maintena PIL

Brintellix® (vortioxetine)

Presentations: 
Brintellix® contains the active substance vortioxetine.
It is available as tablets.

 

SPC & PIL Links:

Click here for the Brintellix tablets SPC

Click here for the Brintellix tablets PIL

Click here for the Brintellix tablets SPC (NI)

Click here for the Brintellix tablets PIL (NI)

Cipralex® (escitalopram)

Presentations: 
Cipralex® contains the active substance escitalopram.
It is available as tablets and oral drops solution.

 

SPC & PIL Links:

Click here for the Cipralex tablets SPC

Click here for the Cipralex tablets PIL

Click here for the Cipralex oral drops solution SPC

Click here for the Cipralex oral drops solution PIL

Cipramil® (citalopram)

 

Presentations: 
Cipramil® contains the active substance citalopram.
It is available as tablets and oral drops solution.

 

SPC & PIL Links:

Click her for the Cipramil tablets SPC

Click here for the Cipramil tablets PIL

Click here for the Cipramil oral drops solution SPC

Click here for the Cipramil oral drops solution PIL

Clopixol® (zuclopenthixol)    

 

Presentations: 
Clopixol® contains the active substance zuclopenthixol.                              
It is available as tablets and injections.

 

SPC & PIL Links:

Click here for the Clopixol tablets SPC

Click here for the Clopixol tablets PIL

Click here for the Clopixol injections SPC

Click here for the Clopixol 200mg/ml injection PIL

Click here for the Clopixol Conc 500mg/ml injection PIL

Clopixol Acuphase® (zuclopenthixol acetate)    

Presentations: 
Clopixol Acuphase® contains the active substance zuclopenthixol acetate.                              
It is available as an injection.

 

SPC & PIL Links:

Click here for the Clopixol Acuphase SPC

Depixol® (flupentixol)

 

Presentations: 

Depixol® contains the active substance flupentixol.
It is available as tablets and injections.

SPC & PIL Links:

Click here for the Depixol tablets SPC

Ebixa® (memantine)

 

Presentations: 

Ebixa® contains the active substance memantine.
It is available as tablets and a pump actuated oral solution.  

SPC & PIL Links:

Click here for the Ebixa 10mg tablets SPC

Click here for the Ebixa 10mg tablets PIL

Click here for Ebixa 20mg tablets SPC

Click here for the Ebixa 20mg tablets PIL

Click here for the Ebixa 10mg tablets SPC (NI)

Click here for the Ebixa 10mg tablets PIL (NI)

Click here for the Ebixa 20mg tablets SPC (NI)

Click here for the Ebixa 20mg tablets PIL (NI)

Click here for the Ebixa tablets, treatment initiation pack SPC

Click here for the Ebixa tablets, treatment initiation pack SPC (NI)

Click here for the Ebixa tablets treatment initiation PIL

Click here for the Ebixa tablets treatment initiation PIL (NI)

Click here for the Ebixa pump actuated oral solution SPC

Click here for the Ebixa pump actuated oral solution PIL

Product: Fluanxol® (flupentixol)

 

Presentations:

Fluanxol® contains the active substance flupentixol.
It is available as tablets.

 

SPC & PIL Links:

Click here for the Fluanxol tablets SPC

Click here for the Fluanxol tablets PIL

Selincro® (nalmefene)

Presentations:

Selincro® contains the active substance nalmefene.

It is available as tablets.

 

SPC & PIL Links:

Click here for the Selincro tablets SPC

More from lundbeck

Research and Development

R&D of new and improved treatments is at the core of what we do.

Patients

We see patients as people and are committed to support the person behind.

Pipeline

Discover our projects and compounds in development. 

UK-NOTPR-1553 | July 2023